ETRA · Electra Therapeutics

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.

230 E Grand Avenue, South San Francisco, CA, 94080, United States
Biotechnology
Healthcare

Market Cap

509.8M

52 Wk Range

$6.87 - $15.50

Previous Close

$8.94

Open

$8.85

Volume

376,123

Day Range

$8.07 - $9.65

Enterprise Value

161.2M

Cash

402.5M

Avg Qtr Burn

-18.91M

Insider Ownership

5.29%

Institutional Own.

94.20%

Qtr Updated

Sep 30th 2026